ViiV Healthcare Revenue and Competitors

Claim your profile

Brentford, UK



Total Funding



Estimated Revenue & Valuation

  • ViiV Healthcare's estimated annual revenue is currently $350.1M per year.(i)
  • ViiV Healthcare's estimated revenue per employee is $201,000

Employee Data

  • ViiV Healthcare has 1742 Employees.(i)
  • ViiV Healthcare grew their employee count by 9% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation

We are ViiV Healthcare: a global specialist HIV company, 100% focused on researching and delivering new medicines and improving access to care for people living with HIV. Our global headquarters are in Brentford, London UK; with our US headquarters in Research Triangle Park, North Carolina. You can read our Social Media Code of Conduct at:



Total Funding


Number of Employees


Revenue (est)


Employee Growth %





ViiV Healthcare News

2022-03-30 - FDA Approves Triumeq, ViiV Healthcare's Daily Treatment for ...

Today, ViiV Healthcare announced that the US Food and Drug Administration (FDA) approved a new drug application (NDA) for their abacavir,...

2022-03-30 - ViiV Healthcare Announces US FDA Approval of Cabenuva ...

ViiV Healthcare is a global specialist HIV company established in November 2009 by GlaxoSmithKline (LSE: GSK) and Pfizer (NYSE: PFE) dedicated...

2022-03-30 - GlaxoSmithKline (GSK) and Pfizer's (PFE) ViiV Healthcare ...

GlaxoSmithKline (GSK) and Pfizer's (PFE) ViiV Healthcare Announces FDA Approval of Cabenuva for HIV. March 29, 2022 1:36 PM. ViiV Healthcare, the global...

2021-10-28 - ViiV Healthcare presents positive interim data showing Vocabria (cabotegravir) and Rekambys (rilpivirine) can be implemented successfully in a variety of European healthcare settings

Issued: London UK ­ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc ("GSK"), with Pfizer Inc. and Shionogi Limited as shareholders, today presented positive interim data from the CARISEL (Cabotegravir and Rilpivirine Implementation Study in European Locat ...

2021-09-28 - SHIONOGI : announces out-licensing agreement with ViiV Healthcare to develop third-generation HIV integrase inhibitor, S-365598.

Press Release SHIONOGI announces out-licensing agreement with ViiV Healthcare to develop third-generation HIV integrase inhibitor, S-365598, with potential for ultra long-acting dosing intervals S-365598 aims to build on the success of dolutegravir and cabotegravir with potential to anchor ...